Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2018 Filed Feb 21, 2018 23:22 UTC |
Shrimpton SeanSenior Vice President
|
GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002516 · edgar.xml · derivative · entry 3 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:23 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantOption (right to buy) · Derivative | 182,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002518 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,935 Underlying: Common shares · 182,935 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,979 on 02/16/2019, 60,978 on 2/16/2020, and 60,978 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:23 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantCommon shares without par value | 33,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002518 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,064 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:30 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002526 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:30 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002526 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,788 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC |
Blaser Brian J.Executive Vice President
|
GrantOption (right to buy) · Derivative | 201,229 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002528 · edgar.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,229 Underlying: Common shares · 201,229 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 67,077 on 02/16/2019, 67,076 on 02/16/2020, and 67,076 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC |
Blaser Brian J.Executive Vice President
|
GrantCommon shares without par value | 36,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002528 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,447 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC |
BIRD ROGERSenior Vice President
|
GrantOption (right to buy) · Derivative | 122,385 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002527 · edgar.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,385 Underlying: Common shares · 122,385 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 40,795 on 02/16/2019, 40,795 on 02/16/2020, and 40,795 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC |
BIRD ROGERSenior Vice President
|
GrantCommon shares without par value | 22,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002527 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,568 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC |
Bracken Sharon JSenior Vice President
|
GrantOption (right to buy) · Derivative | 134,623 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002530 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,623 Underlying: Common shares · 134,623 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,875 on 02/16/2019, 44,874 on 02/16/2020, and 44,874 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC |
Bracken Sharon JSenior Vice President
|
GrantCommon shares without par value | 24,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002530 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,499 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002531 · edgar.xml · derivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002531 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,010 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:36 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 155,495 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002532 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,495 Underlying: Common shares · 155,495 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 51,832 on 02/16/2019, 51,831 on 02/16/2020, and 51,832 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:36 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 28,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002532 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,258 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:37 UTC |
Contreras JaimeSenior Vice President
|
GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002533 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:37 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002533 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,369 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC |
Funck, Jr. Robert E.Vice President, Controller
|
GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002534 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC |
Funck, Jr. Robert E.Vice President, Controller
|
GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002534 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,367 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC |
Ford Robert BExecutive Vice President
|
GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002535 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC |
Ford Robert BExecutive Vice President
|
GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002535 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,075 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:23 UTC |
Fussell Stephen RExecutive Vice President
|
GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · derivative · entry 31 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:23 UTC |
Fussell Stephen RExecutive Vice President
|
GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,884 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:25 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantOption (right to buy) · Derivative | 61,192 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002539 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,192 Underlying: Common shares · 61,192 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,398 on 02/16/2019, 20,397 on 02/16/2020, and 20,397 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:25 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantCommon shares without par value | 11,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002539 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,162 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:26 UTC |
LANE ANDREW HExecutive Vice President
|
GrantOption (right to buy) · Derivative | 182,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002540 · edgar.xml · derivative · entry 3 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,935 Underlying: Common shares · 182,935 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,979 on 02/16/2019, 60,978 on 02/16/2020, and 60,978 on 02/16/2021. Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:48 UTC |
Fussell Stephen RExecutive Vice President
|
SaleCommon shares without par value | 1,000 | $62.68 | $62,680.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,518 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 27,733 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · derivative · entry 14 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 27,733 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 100 | $62.29 | $6,229.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 13 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,854 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 600 | $62.29 | $37,371.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 12 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,954 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 400 | $62.28 | $24,912.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 11 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,554 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 1,340 | $62.28 | $83,448.50 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 10 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,954 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 5,660 | $62.27 | $352,448.20 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 9 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,294 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 2,501 | $62.27 | $155,724.77 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 8 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,954 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 4,613 | $62.26 | $287,205.38 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 7 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,455 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 2,931 | $62.26 | $182,469.41 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 6 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,068 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 6,400 | $62.25 | $398,400.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 5 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,999 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 1,798 | $62.25 | $111,916.51 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 4 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,399 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 500 | $62.24 | $31,120.00 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 3 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,197 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 890 | $62.24 | $55,389.15 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,697 Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:50 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionCommon shares without par value | 27,733 | $22.39 | $620,994.56 |
DisclosureSEC source: 0001179110-18-001378 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 600 | $63.09 | $37,854.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 17 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,166 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 400 | $63.09 | $25,234.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 16 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,766 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 2,400 | $63.08 | $151,392.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 15 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,166 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 100 | $63.08 | $6,307.50 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 14 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,566 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 1,300 | $63.07 | $81,991.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 13 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,666 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 3,000 | $63.06 | $189,180.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 12 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,966 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 202 | $63.06 | $12,737.11 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 11 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,966 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 2,100 | $63.05 | $132,405.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 10 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,168 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC |
Ford Robert BExecutive Vice President
|
SaleCommon shares without par value | 100 | $63.05 | $6,304.50 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 9 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,268 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.